Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission

Dabholkar, Meenakshi; Advani, Suresh H.; Tatake, Revati J.; Gangal, Sudha G.

doi:10.1016/0145-2126(86)90043-3

Cited by 10 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As reported earlier [9] and given in table I, when antibody-coated CRBCs were used as targets, there was no significant difference between the ADCC activ ity of healthy donors and CML low NK responders although the latter showed somewhat reduced cyto toxicity. However, when K562 coated with MAb 4.6E10 were used as targets, the ADCC activity was significantly lower in normal as well as low NK re sponder CML patients (table I).…”

Section: Adcc Activity O F Napbm Nc From Healthy Donors and CM L Patimentioning

confidence: 64%

“…Effector cells cultured at the same density in CM without IL-2 or IFN served as controls in all the experiments. For NK cytotoxicity a 4-hour 51Cr release assay was performed as described earlier [9]. MAh 10 pi culture supernatant containing theanti-K562 MAb 4.6E10 was added to 104 51Cr-labcllcd K562 cells in 100 pi of CM.…”

Section: Separation Anti Treatment O F Effector Cells With Ifn and Il-2mentioning

confidence: 99%

“…In our previous studies we have reported that nonadherenl peripheral blood mononuclear cells (NAPBMNC) from 55% of patients with chronic myeloid leukemia (CML) in remission exhibited sig nificantly reduced NK cytotoxicity (low NK respond ers), while the antibody-dependent cellular cytotoxic ity (ADCC) against chicken RBCs was normal [9], The low NK responder CML patients had NK levels below the mean +2SD of that of healthy donors. The low NK responder status of these CML patients could not be correlated with the clinical status.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Modulation of Natural Killer and Antibody-Dependent Cellular Cytotoxicity by Interferon and Interleukin-2 in Chronic Myeloid Leukemia Patients in Remission

Dabholkar¹,

Tatake²,

Amin³

et al. 1989

Oncology

Self Cite

View full text Add to dashboard Cite

Our earlier studies demonstrated that about 55% of chronic myeloid leukemia (CML) patients in remission exhibited impaired natural killer (NK) cytotoxicity (low NK responders) while antibody-dependent cellular cytotoxicity (ADCC) of these patients, on chicken red blood cells as targets, was within normal range. In this paper, we have attempted to modulate the NK cytotoxicity of CML patients in remission with interferon (IFN) and interleukin-2 (IL-2) singly or together. ADCC using K562 target-directed monoclonal antibody (MAb) 4.6E10 was also modulated by treating the effectors with IFN or IL-2. Pretreatment of nonadherent mononuclear cells from peripheral blood (NAPBMNC) with IFN or IL-2 was found to result in 20 and 21% increase in target cell lysis in case of healthy donors, 79 and 98% increase in case of CML normal NK responders, and 164 and 159% increase in case of CML low NK responders. Combined use of IFN and IL-2 potentiated further the lymphocytotoxicity to 25% in healthy donors, 135% in normal NK responder CML patients and 283% in low NK responder CML patients. This treatment resulted in restoration of cytotoxicity of the latter group of patients to a normal level. The augmentation was seen in 80–100% CML patients. Although ADCC with chicken red blood cells as targets was within normal range, ADCC mediated with MAb to K562 cells was significantly lower in CML low NK responders (24.5%) than CML normal NK responders (42.4%) and healthy donors (65.9%). When the effectors were treated with IL-2 or IFN, much higher ADCC responses were obtained. Combination of treatment of effectors with IL-2 and targets with 4.6E10 augmented the cytotoxicity of low NK responder CML patients to normal levels.

show abstract

Section: Adcc Activity O F Napbm Nc From Healthy Donors and CM L Patimentioning

confidence: 64%

Section: Separation Anti Treatment O F Effector Cells With Ifn and Il-2mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Modulation of Natural Killer and Antibody-Dependent Cellular Cytotoxicity by Interferon and Interleukin-2 in Chronic Myeloid Leukemia Patients in Remission

Dabholkar¹,

Tatake²,

Amin³

et al. 1989

Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The NK and LAK cell activities were determined using the standard four-hour 5"Chromium release assay (Dabholkar et al, 1986;Tatake et al, 1989). The NK-sensitive targets used were K562 cells.…”

Section: Cytotoxicity Assay and Targetsmentioning

confidence: 99%

“…The frequency of LAK cell precursors has also been studied using limiting dilution analysis (LDA Separation of lymphocytes PBL were separated on Ficoll-Hypaque (FH) gradient (Pharmacia, Sweden). The non-adherent PBL were obtained to assess NK activity as described before (Dabholkar et al, 1986). LAK cells were generated from the total PBL population using the predetermined optimum dose of 10 u recombinant IL-2 (rIL-2, Biogen, S.A., Switzerland) per 1 x 106 lymphocytes (Tatake et al, 1989).…”

mentioning

confidence: 99%

Natural killer and lymphokine activated killer cell functions in Hodgkin's disease

Rajaram¹,

Tatake²,

Advani³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Summary We report the natural killer (NK) and lymphokine activated killer (LAK) cell activities in peripheral blood lymphocytes (PBL) from untreated patients with Hodgkin's disease (HD) and from healthy donors. The frequency of LAK cell precursors was also studied using limiting dilution analysis (LDA). About 75% of the HD patients had normal NK activity. There was a higher percentage of low NK responders (mean percent NK activity of healthy donors -2 SD) in patients with lymphocyte depletion histologic grade of the disease and those who were in clinical stage IV, suggesting a correlation of decrease in NK activity with poor prognosis. We found efficient LAK activity against the NK-sensitive K562 cells and NK-resistant VIP (melanoma) and T-24 (bladder carcinoma) tumour targets in both low and normal NK responder HD patients, irrespective of the histopathological grade and clinical stage of the disease. In concordance with their good LAK cell activity, HD patients showed a frequency distribution of LAK cell progenitors in the PBL comparable to that of healthy donors.

show abstract

In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission

Somasundaram

Rao

Advani

et al. 1988

Cancer Immunol Immunother

View full text Add to dashboard Cite

Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission

Cited by 10 publications

References 25 publications

Modulation of Natural Killer and Antibody-Dependent Cellular Cytotoxicity by Interferon and Interleukin-2 in Chronic Myeloid Leukemia Patients in Remission

Modulation of Natural Killer and Antibody-Dependent Cellular Cytotoxicity by Interferon and Interleukin-2 in Chronic Myeloid Leukemia Patients in Remission

Natural killer and lymphokine activated killer cell functions in Hodgkin's disease

In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission

Contact Info

Product

Resources

About